UNCY - NASDAQ
Unicycive Therapeutics, Inc.
$7.50
+4.7%Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
At a Glance
Live SnapshotUnicycive Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Unicycive Therapeutics, Inc. Cash Flow Statement
UNCY • NASDAQ
| Unicycive Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-26.6M | -36.7M | -30.5M | -18.1M | -10M | -2.3M | -2.2M | -1.1M | |
572K | 428K | 284K | 161K | 13K | 0.0 | 0.0 | 0.0 | |
2.6M | 2.4M | 1.8M | 1M | 966K | 232K | 24K | 0.0 | |
-2M | 5.8M | 10.3M | 21K | 3.4M | 739K | 660K | 308K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1K) | (0.0) | (0.0) | |
-6M | -427K | -93K | 1.2M | -105K | -166K | 305K | 6K | |
-31.3M | -28.6M | -18.3M | -15.7M | -5.8M | -1.5M | -1.2M | -775K | |
INVESTING ACTIVITIES | ||||||||
-24K | -72K | -12K | -2K | -29K | (0.0) | (0.0) | (0.0) | |
-12.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-12.1M | -72K | -12K | -2K | -29K | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||
48.1M | 683K | 0.0 | 11K | 22.3M | 141K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -15K | 1.4M | 0.0 | 0.0 | |
(0.0) | -1.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.6M | -4.5M | -2.6M | -482K | 119K | -117K | 1.2M | 800K | |
46.5M | 45.1M | 27.5M | -471K | 22.4M | 1.4M | 1.2M | 800K | |
CASH FLOW SUMMARY | ||||||||
3.1M | 16.4M | 9.2M | -16.1M | 16.6M | -15K | -10K | 25K | |
26.1M | 9.7M | 455K | 16.6M | 0.0 | 15K | 25K | 0.0 | |
29.2M | 26.1M | 9.7M | 455K | 16.6M | 0.0 | 15K | 25K | |
-31.3M | -28.6M | -18.3M | -15.7M | -5.8M | -1.5M | -1.2M | -775K |
SEC Filings
UNCY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 |
Related Guides
Continue your UNCY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.